FDA sets back review date of Acorda’s levodopa inhaler for Parkinson’s disease

FDA
The agency set a new review deadline for Acorda’s levodopa inhaler, for Jan. 5, 2019, after requesting more info on its chemistry, manufacturing and controls. (FDA)

Acorda Therapeutics’ share price took a beating this week, losing about a third of its value after a one-two punch from the courts and the FDA, which extended its review of its drug-device combination treatment for Parkinson’s disease by three months.

The agency pushed back the PDUFA date of Acorda’s inhaled levodopa therapy Inbrija from Oct. 5 to Jan. 5, 2019. In a statement, the company said the FDA requested additional information on chemistry, manufacturing and controls, and the major amendment to its application will take additional time to review.

And the Monday before, a federal appeals court upheld a ruling invalidating four patents for Acorda’s main moneymaking drug, multiple sclerosis muscle-strengthener Ampyra, with generics on the way.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

That day, Acorda CEO Ron Cohen, M.D., said the company was reviewing its options, including another appeal, and that it was “well-capitalized and fully focused on the potential launch of Inbrija for Parkinson’s disease.” In the second quarter of this year, Ampyra accounted for $150.3 million of Acorda’s $153.3 million in revenue.

RELATED: Under threat of early Ampyra knockoffs, Acorda plans to chop 100 jobs

Come Thursday, Cohen made a new statement: “We look forward to continuing our constructive dialogue with FDA.”

Inbrija had a rough start at the agency, which initially refused to file Acorda’s application in August 2017—due to questions regarding when its Chelsea, Massachusetts, drug manufacturing site would be ready for a preapproval inspection, as well as its master production records. The inhaler itself is being supplied by a contractor.

The FDA accepted Inbrija’s application for review in February. The self-administered therapy is designed to treat the symptoms of “Off” periods on an as-needed basis, for Parkinson’s disease patients taking a carbidopa/levodopa regimen.